CMMB Description — Chemomab Therapeutics Ltd
Chemomab Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of targeted therapies to treat cancer. Co. is developing small-molecule pan-RAS inhibitors and inhibitors of phosphodiesterase (PDE10) and the ß-catenin pathway. Co.'s pan-RAS program has identified indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition. Co.'s PDE10/ß-catenin program has identified small molecules that inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models.
|
Free CMMB Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|